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Introduction
Adult T-cell leukemia/lymphoma (ATLL) caused by
human retrovirus, HTLV-1, is a neoplasm of mature
T-cell. In Japan, more than a thousand patients with
ATLL die every year incurable with median survival
time less than one year. We aim to investigate clinical
value of soluble CD30 (sCD30) levels in sera on predic-
tion of short term mortality and overall survival (OS) in
ATLL patients.
Methods
Between September 2005 and December 2010, a prospec-
tive cohort study was done in 60 ATLL patients treated
with chemotherapy or allogeneic hematopoietic stem cell
transplantation (HSCT) at the Department of Hematology,
National Hospital Organization Kumamoto Medical
Center, Japan. Univariate analysis of OS was performed
using the Kaplan-Meier method to estimate survival prob-
abilities in patient subgroups, and the log-rank test was
used for statistical comparisons.
Results
In the patients undergoing chemotherapy, pre-treatment
status of BUN, creatinine, AST, ALT ALP, total bilirubin,
LDH, serum albumin, corrected calcium, platelet, percen-
tage of malignant cells in peripheral blood, serum sCD30
level, serum soluble IL-2 receptor level, performance sta-
tus and Charlson’s comorbidity index were the risk factors
of two-year OS. In patients undergoing HSCT, pre-treat-
ment status of source of stem cells, HLA matching, BUN,
LDH, corrected calcium, CRP, serum sCD30 level, and
Charlson’s comorbidity index were the significant risk fac-
tors of two-year OS. Our result suggested that sCD30 was
the common significant risk factor of chemotherapy and
HSCT in two-year OS.
Conclusion
sCD30 may be a new biomarker for newly-diagnosed
ATLL. The combination of various factors can provide
useful information of OS prediction.
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